Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 1
2010 3
2011 5
2012 6
2013 15
2014 15
2015 16
2016 9
2017 13
2018 5
2019 12
2020 43
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

137 results
Results by year
Filters applied: . Clear all
Page 1
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. Pharmacol Res. 2020. PMID: 31862477 Review.
The US FDA approved four small molecule protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fedratinib. Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for RO …
The US FDA approved four small molecule protein kinase antagonists in 2019; these include entrectinib, erdafitinib, pexidartinib, and fed
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D, Yang XO. Wu D, et al. J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11. J Microbiol Immunol Infect. 2020. PMID: 32205092 Free PMC article.
We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles....
We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to induce clinical responses and improve symptoms in patients previously treated with ruxolitinib. Fedratinib induces robust spleen response
Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to indu
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM. Bewersdorf JP, et al. Cancer Manag Res. 2019 Dec 24;11:10777-10790. doi: 10.2147/CMAR.S212559. eCollection 2019. Cancer Manag Res. 2019. PMID: 31920387 Free PMC article. Review.
The main side effects of fedratinib include anemia, gastrointestinal symptoms, and elevations in liver transaminases. Fedratinib also has ablack box warning for encephalopathy, although this occurred only in about 1% of the treated patients, most of which were ultim …
The main side effects of fedratinib include anemia, gastrointestinal symptoms, and elevations in liver transaminases. Fedratinib
Novel treatment strategies for myeloproliferative neoplasms.
Bose P, Masarova L, Verstovsek S. Bose P, et al. Rinsho Ketsueki. 2019;60(9):1176-1185. doi: 10.11406/rinketsu.60.1176. Rinsho Ketsueki. 2019. PMID: 31597841 Review.
Although the Janus kinase (JAK) inhibitor ruxolitinib has long been the only drug licensed for treatment of the classic Philadelphia chromosome negative (Ph(-)) myeloproliferative neoplasms, years of drug development efforts have begun to bear fruit with the recent approval of a …
Although the Janus kinase (JAK) inhibitor ruxolitinib has long been the only drug licensed for treatment of the classic Philadelphia chromos …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Review.
In non-transplant candidates, conventional treatment for anemia includes androgens, prednisone, thalidomide, and danazol; for symptomatic splenomegaly, hydroxyurea and ruxolitinib; and for constitutional symptoms, ruxolitinib. Fedratinib, another JAK2 inhibitor, has now be …
In non-transplant candidates, conventional treatment for anemia includes androgens, prednisone, thalidomide, and danazol; for symptomatic sp …
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.
Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN. Pitroda SP, et al. Mol Cancer Ther. 2018 Apr;17(4):732-739. doi: 10.1158/1535-7163.MCT-17-0667. Epub 2018 Feb 21. Mol Cancer Ther. 2018. PMID: 29467274 Free article.
However, less than 15% of patients survive beyond 5 years. Here, we investigated the effects of SAR302503 (SAR), a selective JAK2 inhibitor, on NSCLC cell lines and tumors. ...
However, less than 15% of patients survive beyond 5 years. Here, we investigated the effects of SAR302503 (SAR), a selective JAK2 inh …
Fedratinib: First Approval.
Blair HA. Blair HA. Drugs. 2019 Oct;79(15):1719-1725. doi: 10.1007/s40265-019-01205-x. Drugs. 2019. PMID: 31571162 Review.
Fedratinib (INREBIC()) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. ...This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis....
Fedratinib (INREBIC()) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. ...This article
Novel therapeutics in myeloproliferative neoplasms.
Venugopal S, Mascarenhas J. Venugopal S, et al. J Hematol Oncol. 2020 Dec 2;13(1):162. doi: 10.1186/s13045-020-00995-y. J Hematol Oncol. 2020. PMID: 33267911 Free PMC article. Review.
The United States Food and Drug Administration's (USFDA) approval of two JAK inhibitors (ruxolitinib, fedratinib) has transformed the therapeutic landscape of MPNs in assuaging the need for frequent therapeutic phlebotomy (PV) and reduction in spleen and symptom burden (PV …
The United States Food and Drug Administration's (USFDA) approval of two JAK inhibitors (ruxolitinib, fedratinib) has transformed the …
137 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page